心包内博来霉素治疗恶性心包积液：重新审视靶向药理学方法。

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiovascular Pharmacology Pub Date : 2025-10-01 DOI:10.1097/FJC.0000000000001746

Danny L Rayes, Hira Latif, Syed Waqas Haider

引用次数: 0

摘要

恶性心包积液是晚期恶性肿瘤的一种并发症，预后差，在心包填塞的情况下可能危及生命。由于复发率高，治疗具有挑战性。治疗方案包括心包开窗手术、延长导管引流或心包内硬化剂。虽然手术仍然是符合条件的患者最明确的选择，但虚弱和手术并发症是主要的限制。有限的证据表明，硬化剂提供了相当的疗效与改善耐受性。博莱霉素是一种具有双重细胞毒性和硬化作用的糖肽类抗生素，已成为一种有希望的替代方案，最近的证据表明，与其他药物相比，博莱霉素的疗效与手术引流相似，耐受性更好。我们强调博来霉素的优势及其作为治疗恶性心包积液的有效、耐受性良好和姑息性选择的广泛应用潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Intrapericardial Bleomycin for Malignant Pericardial Effusion: Revisiting a Targeted Pharmacologic Approach.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Cardiovascular Pharmacology 医学-心血管系统

CiteScore

5.10

自引率

3.30%

发文量

367

审稿时长

1 months

期刊介绍： Journal of Cardiovascular Pharmacology is a peer reviewed, multidisciplinary journal that publishes original articles and pertinent review articles on basic and clinical aspects of cardiovascular pharmacology. The Journal encourages submission in all aspects of cardiovascular pharmacology/medicine including, but not limited to: stroke, kidney disease, lipid disorders, diabetes, systemic and pulmonary hypertension, cancer angiogenesis, neural and hormonal control of the circulation, sepsis, neurodegenerative diseases with a vascular component, cardiac and vascular remodeling, heart failure, angina, anticoagulants/antiplatelet agents, drugs/agents that affect vascular smooth muscle, and arrhythmias. Appropriate subjects include new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects, application of drugs to gain novel insights into physiology or pathological conditions, clinical results with new and established agents, and novel methods. The focus is on pharmacology in its broadest applications, incorporating not only traditional approaches, but new approaches to the development of pharmacological agents and the prevention and treatment of cardiovascular diseases. Please note that JCVP does not publish work based on biological extracts of mixed and uncertain chemical composition or unknown concentration.